KalVista Pharmaceuticals (KALV) Net Income towards Common Stockholders Growth (5y) (2021 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -33.50% |
| Apr 30, 2025 | 45.79% |
| Oct 31, 2024 | -38.31% |
| Jul 31, 2024 | -35.14% |
| Apr 30, 2024 | 36.26% |
| Jan 31, 2024 | -37.36% |
| Oct 31, 2023 | -43.94% |
| Jul 31, 2023 | -32.41% |
| Apr 30, 2023 | -116.04% |
| Jan 31, 2023 | -38.02% |
| Oct 31, 2022 | -38.53% |
| Jul 31, 2022 | -39.54% |
| Apr 30, 2022 | -44.58% |
| Jan 31, 2022 | -27.46% |
| Oct 31, 2021 | -40.61% |
| Jul 31, 2021 | -33.87% |